IP Library Granted Patent US 10,744,112
Granted Patent B2
US 10,744,112 · App. 16/463,814 · Granted Aug 18, 2020

Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds

Inventor: Claire Mallard (Mougins, FR)
Assignee: NESTLÉ SKIN HEALTH S.A.
A61K31/343A61K9/0014A61K9/06A61K9/10A61K9/107A61K31/7048A61P17/00A61P17/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,744,112
App. No.
16/463,814
Granted
Aug 18, 2020
Kind
B2
Abstract

Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and a least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.

Claims (19)

1. A dermatological or pharmaceutical composition comprising:

(a) at least one aqueous phase;

(b) at least one fatty phase comprising (i) 5 to 10% by weight, relative to the total weight of the composition, of one or more fatty compounds selected from vegetable oils, mineral oils, animal oils, synthetic oils, silicone oils, fatty acids, fatty alcohols, fatty acid alcohol esters, waxes, gums, and mixtures thereof and (ii) at least one active compound chosen from avermectin compounds; and

(c) 0.01 to 1% by weight, relative to the total weight of the composition, of one or more antioxidant agents chosen from the group consisting of butylhydroxyanisole, tocopherol, tocopherol acetate, ascorbic acid, ascorbic palmitate, propyl gallate, sodium metabisulfite, butylhydroxytoluene, and mixtures thereof,

wherein the composition does not comprise solvents and/or propenetrating agents of avermectin compounds selected from the group consisting of propylene glycol, ethanol, isopropanol, butanol, N-methyl-2-pyrrolidone, dimethylsulfoxyde, polysorbate 80, poloxamer 124, phenoxyethanol, oleyl alcohol, isostearic acid, diisopropyl adipate, polypropylene glycol-15 stearyl ether (“PPG-15 stearyl ether”), octyl dodecanol, ethyl oleate, C 12 -C 15 alkyl benzoate, and mixtures thereof.

2. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the avermectin compounds are chosen from ivermectin, invermectin, avermectin, abamectin, doramectin, eprinomectin and selamectin.

3. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the avermectin compound is ivermectin.

4. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the composition comprises from 0.01 to 10% by weight, of avermectin compounds, relative to the total weight of the composition.

5. The dermatological or pharmaceutical composition as defined in claim 4 , wherein the composition comprises from 0.1 to 5% by weight of avermectin compounds, relative to the total weight of the composition.

6. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the fatty compounds are chosen from fatty acid alcohol esters, silicone oils, fatty alcohols, and mixtures thereof.

7. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the composition comprises one or more surfactants.

8. The dermatological or pharmaceutical composition as defined in claim 7 , wherein the surfactants are chosen from non-ionic surfactants.

9. The dermatological or pharmaceutical composition as defined in claim 7 , wherein the surfactants are chosen from polyoxyethylenated fatty alcohol ethers, sorbitan esters, and mixtures thereof.

10. The dermatological or pharmaceutical composition as defined in claim 7 , wherein the composition comprises from 0.1 to 10% by weight of surfactants, relative to the total weight of the composition.

11. The dermatological or pharmaceutical composition as defined in claim 10 , wherein the composition comprises from 1 to 7% by weight of surfactants, relative to the total weight of the composition.

12. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the composition comprises from 10 to 90% of fatty phase and from 10 to 90% of aqueous phase.

13. The dermatological or pharmaceutical composition as defined in claim 1 , wherein the composition comprises from 10 to 30% of fatty phase and from 70 to 90% of aqueous phase.

14. A method of treating rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, comprising administering to a subject in need thereof a compositions as defined in claim 1 .

15. The method as defined in claim 14 , wherein the composition is administered topically.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
CHANGE OF NAME Recorded Dec 31, 2020
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 054899/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2020
From: MALLARD, CLAIRE
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 052779/0294 →